AptaBio Therapeutics Inc Total Liabilities

Latest as of September 2025: ₩22.51 Billion KRW ≈ $15.25 Million USD

AptaBio Therapeutics Inc total liabilities. Based on the latest financial reports, AptaBio Therapeutics Inc (293780) has total liabilities worth ₩22.51 Billion KRW (≈ $15.25 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 293780 financial resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of AptaBio Therapeutics Inc (2017–2024)

Total liabilities of AptaBio Therapeutics Inc from 2017 to 2024. This chart illustrates how AptaBio Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.

AptaBio Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of AptaBio Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
OBOOK Holdings Inc. Class A Common Shares NASDAQ:OWLS	USA	$30.60 Million
51 TALK ONL. SP.ADR A 60 F:C4G0	Germany	€98.81 Million
Shanghai Bailian Group Co Ltd B SHG:900923	China	$32.38 Billion
Korea Fuel-Tech Corporation KQ:123410	Korea	₩286.07 Billion
Kingwaytek Technology Co Ltd TWO:6516	Taiwan	NT$261.79 Million
Bank Qnb Indonesia Tbk JK:BKSW	Indonesia	Rp8.42 Trillion
Chung Fu Tex-International Corp TW:1435	Taiwan	NT$185.59 Million
IL Science Co. Ltd KQ:307180	Korea	₩125.87 Billion

Liability Composition Analysis (2017–2024)

This chart breaks down AptaBio Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of AptaBio Therapeutics Inc.

Liquidity & Leverage Metrics

AptaBio Therapeutics Inc Total Liabilities Ratios Explained

AptaBio Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.27	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.34	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how AptaBio Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for AptaBio Therapeutics Inc (2017–2024)

The table below shows the annual total liabilities of AptaBio Therapeutics Inc from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩23.24 Billion ≈ $15.75 Million	-25.42%
2023-12-31	₩31.16 Billion ≈ $21.11 Million	+732.10%
2022-12-31	₩3.74 Billion ≈ $2.54 Million	+15.36%
2021-12-31	₩3.25 Billion ≈ $2.20 Million	-4.64%
2020-12-31	₩3.40 Billion ≈ $2.31 Million	+51.33%
2019-12-31	₩2.25 Billion ≈ $1.52 Million	+11.52%
2018-12-31	₩2.02 Billion ≈ $1.37 Million	-95.26%
2017-12-31	₩42.54 Billion ≈ $28.83 Million	--

About AptaBio Therapeutics Inc

KQ:293780 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$92.73 Million

₩136.83 Billion KRW

Market Cap Rank

#19309 Global

#947 in Korea

Share Price

₩5090.00

Change (1 day)

-4.14%

52-Week Range

₩4000.00 - ₩10420.00

All Time High

₩61500.00